Pramodini Kale-Pradhan

Dr. Pramodini Kale-Pradhan

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
CGChristopher Giuliano
Christopher Giuliano
SWSheila M Wilhelm
Sheila M Wilhelm
PKPramodini Kale-Pradhan
Pramodini Kale-Pradhan
(2012). Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Review of Clinical Pharmacology: Vol. 5, No. 3, pp. 337-344. doi: 10.1586/ecp.12.20

1 July 2013 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
SWSheila M Wilhelm
Sheila M Wilhelm
RRRyan G Rjater
Ryan G Rjater
PKPramodini Kale-Pradhan
Pramodini Kale-Pradhan
This review summarizes the literature regarding long-term adverse effects of proton pump inhibitors (PPIs). A PubMed search (1966 to February 2013) for English language studies was conducted using key terms PPI: omeprazole, esomeprazole, pantoprazole, lansoprazole, dexlansoprazole, rabeprazole, pneumonia, Clostridium difficile, osteoporosis, risk of fractures, thrombocytopenia, rhabdomyolysis, anemia, iron deficiency, hypomagnesemia, vitamin B₁₂ and nephritis. The risk of pneumonia was increased 27-39% in short-term use of PPIs in three meta-analyses. C. difficile infections were also associated with the use of PPIs (odds ratio: 2.15; 95% CI: 1.81-2.55; p < 0.00001). This effect appears to be dose related. The US FDA has recently issued a warning regarding fractures and the impaired magnesium absorption associated with the use of PPI. Thrombocytopenia, iron deficiency, vitamin B12 deficiency, rhabdomyolysis and acute interstitial nephritis have also been reported with the use of PPIs. There is mounting evidence that PPIs are associated with serious adverse effects. Practitioners should be vigilant and counsel patients accordingly.

24 March 2014 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
SWSheila M. Wilhelm
Sheila M. Wilhelm
JYJamie Young
Jamie Young
PKPramodini Kale-Pradhan
Pramodini Kale-Pradhan
Purpose: Obesity is a growing epidemic leading to worldwide public health concerns. Bariatric surgery is an option for patients with a body mass index (BMI) >40 kg/m 2 or BMI of >35 kg/m 2 with serious comorbid conditions. This meta-analysis examines the effect of bariatric surgery on the improvement or resolution of hypertension. Methods: Two independent investigators conducted a literature search of PubMed (1990-2013) and Cochrane databases using the terms bariatric surgery and hypertension to identify appropriate human adult studies published in English. Studies were included if they reported the number of patients with hypertension prior to undergoing any bariatric surgery procedure and whether the hypertension improved or resolved postsurgery. The number of patients with hypertension and their response rates were extracted and analyzed using RevMan 5.2.5. Results: In all, 31 prospective and 26 retrospective studies met all criteria. The types of bariatric surgery performed included Roux-en-Y, gastric banding, laparoscopic adjustable gastric banding, vertical gastric banding, sleeve gastrectomy, duodenal switch, and biliopancreatic diversion. The time to first follow-up after surgery varied from 1 week to 7 years. Of the 57 studies, 32 reported improvement of hypertension in 32 628 of 51 241 patients (odds ratio [OR] = 13.24; 95% CI = 7.73, 22.68; P < 0.00001); 46 studies reported the resolution of hypertension in 24 902 of 49 844 patients (OR = 1.70; 95% CI = 1.13, 2.58; P = 0.01). A random-effects model was used because the heterogeneity between the studies was high ( I 2 = 97%). Conclusion: The results of this meta-analysis indicate that patients who undergo bariatric surgery experience improvement and resolution of their hypertension.

1 March 2010 in American Journal of Infection Control
Verified
Journal Article
Closed access
BRBasel Al Raiy
Basel Al Raiy
MFMohamad G. Fakih
Mohamad G. Fakih
NBNicole Bryan-Nomides
Nicole Bryan-Nomides
DHDebi Hopfner
Debi Hopfner
ERElizabeth Riegel
Elizabeth Riegel
RKRiad Khatib
Riad Khatib

1 February 2010 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
PKPramodini Kale-Pradhan
Pramodini Kale-Pradhan
HJHarjot K. Jassaly
Harjot K. Jassaly
SWSheila M. Wilhelm
Sheila M. Wilhelm

7 November 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
BSBeth Schwartz
Beth Schwartz
KKKatherine Klamer
Katherine Klamer
JZJustin M Zimmerman
Justin M Zimmerman
PKPramodini Kale-Pradhan
Pramodini Kale-Pradhan
ABAshish Bhargava
Ashish Bhargava
Pseudomonas aeruginosa is causing increasing concern among clinicians due to its high mortality and resistance rates. This bacterium is responsible for various infections, especially in hospital settings, affecting some of the most vulnerable patients. Pseudomonas aeruginosa has developed resistance through multiple mechanisms, making treatment challenging. Diagnostic techniques are evolving, with rapid testing systems providing results within 4–6 h. New antimicrobial agents are continuously being developed, offering potential solutions to these complex clinical decisions. This article provides a review of the epidemiology, at-risk populations, resistance mechanisms, and diagnostic and treatment options for Pseudomonas aeruginosa.